Shire submits IND application for SHP654 to treat haemophilia A

Irish-based Shire has submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for SHP654, also designated as BAX 888, an investigational factor VIII (FVIII) gene therapy to treat haemophilia A.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news